Valeant Pharma (VRX): Salix Sale Resolves Nothing - Mizuho

November 2, 2016 7:20 AM EDT
Get Alerts VRX Hot Sheet
Price: $14.90 --0%

Rating Summary:
    10 Buy, 12 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 24 | New: 12
Trade VRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Mizuho Securities analyst, Irina Koffler, reiterated her Neutral rating on shares of Valeant Pharmaceuticals (NYSE: VRX) noting that the Salix sale resolves "nothing".

The analyst believes the financial impact will be nominal and the 33% increase overestimates the importance. No change to the price target of $25.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $23.86 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Mergers and Acquisitions

Related Entities

Irina Koffler

Add Your Comment